Clinical Trial Update: Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A two-arm Phase 1/2a dose-escalation study of BAX69 in patients with malignant ascites due to refractory ovarian cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites
• Ovarian Cancer

Drugs mentioned

• BAX69

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-06-15